Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation

Clinical Transplantation

Volumn 26, Issue 1, 2012, Pages 57-66

  Stracke, Sylvia ^a   Shipkova, Maria ^b   Mayer, Jens ^c   Keller, Frieder ^d   Zarghom, Amir ^d   Yang, Liying ^b   Henne Bruns, Doris ^d   Wieland, Eberhard ^c  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b KLINIKUM STUTTGART   (Germany)

^c General and Visceral Surgery   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Acyl glucuronide; Enteric coated mycophenolate sodium; Immunosuppression; IMPDH; Kidney transplantation; Mycophenolic acid

Indexed keywords

CYCLOSPORIN; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; STEROID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIODE ARRAY DETECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOCYTE; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; SIROLIMUS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84856647754     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01403.x     Document Type: Article

References (39)

1. Salvadori M, Holzer H, De Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant recipients. Am J Transplant 2004: 4: 231.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007: 46: 13.
3. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005: 1: 505.
4. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007: 39: 88.
5. Davies NM, Grinyó J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007: 22: 2440.
6. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006: 82: 1413.
7. Budde K, Bauer S, Hambach P et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007: 7: 888.
8. Legendre C, Cohen D, Zeier M, Rostaing L, Budde K. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc 2007: 39: 1386.
9. Nashan B, Suwelack B, Ivens K et al. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Transplant Proc 2006: 38: 2856.
10. Salvadori M, Holzer H, Civati G et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 2006: 66: 112.
11. Arns W, Gies M, Choi L et al. Absorption characteristics of EC-MPS - an enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 2006: 44: 375.
12. Van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006: 28: 145.
13. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998: 64: 672.
14. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002: 13: 759.
15. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007: 7: 2496.
16. Van Gelder T, Silva HT, De Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008: 86: 1043.
17. Borrows R, Chusney G, Loucaidou M et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006: 6: 121.
18. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007: 2: 1062.
19. Budde K, Tedesco-Silva H, Pestana JM et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 2007: 29: 381.
20. Glander P, Braun KP, Hambach P et al. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001: 34: 543.
21. Levey AS, Coresh J, Greene T et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007: 53: 766.
22. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005: 16: 763.
23. Shipkova M, Niedmann PD, Armstrong VW et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998: 44: 1481.
24. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000: 46: 365.
25. Glander P, Sommerer C, Arns W et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010: 5: 503.
26. Neumann I, Fuhrmann H, Kanzler M et al. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. Expert Opin Pharmacother 2008: 9: 879.
27. Cattaneo D, Cortinovis M, Baldelli S et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007: 2: 1147.
28. Hummel M, Yonan N, Ross H et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007: 21: 18.
29. Granger DK, ERL B 301 Renal Transplant Study Group, ERL B 302 Renal Transplant Study Group. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001: 33: 3241.
30. Sumethkul V, Na-Bangchang K, Kantachuvesiri S, Jirasiritham S. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. Transplant Proc 2005: 37: 861.
31. Czock D, Rasche FM, Carius A et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol 2007: 47: 850.
32. Cattaneo D, Gaspari F, Ferrari S et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001: 15: 402.
33. Atcheson BA, Taylor PJ, Mudge DW et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005: 59: 271.
34. De Winter BC, Van Gelder T, Glander P et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008: 47: 827.
35. Tedesco-Silva H, Bastien MC, Choi L et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005: 37: 852.
36. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003: 25: 1.
37. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999: 45: 419.
38. Sombogaard F, Peeters AM, Baan CC et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009: 31: 549.
39. Hasche G, Wieland E, Shipkova M et al. Association between pharmacokinetics (PK), pharmacodynamics (PD), and clinical events under therapy with mycophenolic acid (EC-MPS) in the early phase after kidney transplantation (KTx). J Am Soc Nephrol 2008: 19: 677A (Abstr.).